VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
XOMAPXOMA Corporation
$25.44$307M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

XOMAP logoXOMA Corporation(XOMAP)Earnings, Financials & Key Ratios

XOMAP•NASDAQ
17.4× P/E·Price updated Jun 19, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryRoyalty and IP Monetization Vehicles
AboutXOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Show more
  • Revenue$52M+83.1%
  • EBITDA$14M+136.1%
  • Net Income$32M+329.4%
  • EPS (Diluted)1.46+188.5%
  • Gross Margin94.32%-5.0%
  • EBITDA Margin27.53%+119.7%
  • Operating Margin21.83%+115.6%
  • Net Margin60.81%+225.3%
  • ROE34.12%+310.6%

XOMAP Key Insights

XOMA Corporation (XOMAP) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y profit CAGR of 19.0%
  • ✓Strong 5Y sales CAGR of 12.2%

✗Weaknesses

  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Shares diluted 53.7% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when XOMAP posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

XOMAP Price & Volume

XOMA Corporation (XOMAP) stock price & volume — 10-year historical chart

Loading chart...

XOMAP Growth Metrics

XOMA Corporation (XOMAP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-0.61%
5 Years12.16%
3 Years105.3%
TTM-36.12%

Profit CAGR

10 Years-
5 Years18.98%
3 Years-
TTM1282.58%

EPS CAGR

10 Years-
5 Years13.36%
3 Years-
TTM468.97%

Return on Capital

10 Years-22.21%
5 Years-7.44%
3 Years-12.74%
Last Year5.24%

XOMAP Recent Earnings

XOMA Corporation (XOMAP) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 5/12 qtrs (83%)●Beat Revenue 4/12 qtrs (67%)
Q2 2026Latest
May 12, 2026
Metric
Actual
Est
EPS
$0.17+30.5%
$0.13
Rev
$14M+0.3%
$14M
Q2 2026
Mar 18, 2026
Metric
Actual
Est
EPS
$0.26+327.0%
$0.11
Rev
$14M+24.5%
$11M
Q4 2025
Nov 12, 2025
Metric
Actual
Est
EPS
$0.78+2050.0%
$0.04
Rev
$9M-18.5%
$11M
Q3 2025
Aug 15, 2025
Metric
Actual
Est
EPS
$0.61+508.7%
$0.15
Rev
$13M+19.4%
$11M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 12, 2026
$0.17vs $0.13+30.5%
$14Mvs $14M+0.3%
Q2 2026Mar 18, 2026
$0.26vs $0.11+327.0%
$14Mvs $11M+24.5%
Q4 2025Nov 12, 2025
$0.78vs $0.04+2050.0%
$9Mvs $11M-18.5%
Q3 2025Aug 15, 2025
$0.61vs $0.15+508.7%
$13Mvs $11M+19.4%
Based on last 12 quarters of dataView full earnings history →

XOMAP Peer Comparison

XOMA Corporation (XOMAP) competitors in Royalty and IP Monetization Vehicles — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
BCYC logoBCYCBicycle Therapeutics plcDirect Competitor277.05M4.00-1.27105.77%-344.95%-35.74%0.03
PRTC logoPRTCPureTech Health plcDirect Competitor41.78M17.31-0.38-3.5%-6.25%-16.12%0.06
NUVB logoNUVBNuvation Bio Inc.Direct Competitor1.93B5.56-9.276.99%-102.06%-44.1%0.03
RCUS logoRCUSArcus Biosciences, Inc.Product Competitor2.45B24.31-7.39-4.26%-156.36%-68.97%0.16
PRAX logoPRAXPraxis Precision Medicines, Inc.Product Competitor8.15B282.31-20.94-100%-43.02%0.00
ANAB logoANABAnaptysBio, Inc.Product Competitor2.48B57.51-125.02157.01%-11.53%-24.49%0.38
IMVT logoIMVTImmunovant, Inc.Product Competitor7.26B35.34-12.76-68.16%0.00
ABBV logoABBVAbbVie Inc.Supply Chain383.17B216.6391.418.57%6.91%62.15%

Compare XOMAP vs Peers

XOMA Corporation (XOMAP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BCYC

Most directly comparable listed peer for XOMAP.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare XOMAP against a more recognizable public peer.

Peer Set

Compare Top 5

vs BCYC, PRTC, NUVB, RCUS

XOMAP Income Statement

XOMA Corporation (XOMAP) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
52.69M5.3M18.37M29.39M38.16M6.03M4.76M28.49M52.15M27.41M
Revenue Growth %
846.98%-89.94%246.67%59.96%29.86%-84.21%-21.06%498.72%83.06%-36.12%
Cost of Goods Sold
7.88M1.68M1.25M170K171K274K143K206K2.96M1.55M
COGS % of Revenue
14.95%31.74%6.82%0.58%0.45%4.55%3.01%0.72%5.68%-
Gross Profit
44.81M▲ 0%
3.62M▼ 91.9%
17.12M▲ 373.2%
29.21M▲ 70.7%
37.99M▲ 30.0%
5.75M▼ 84.9%
4.62M▼ 19.8%
28.28M▲ 512.8%
49.19M▲ 73.9%
25.86M▲ 0%
Gross Margin %
85.05%68.26%93.18%99.42%99.55%95.45%96.99%99.28%94.32%94.35%
Gross Profit Growth %
976.25%-91.93%373.24%70.68%30.03%-84.86%-19.78%512.81%73.93%-
Operating Expenses
32.21M20.25M21M16.8M20.46M23.17M46.46M68.26M37.8M20.89M
OpEx % of Revenue
61.13%382.05%114.33%57.17%53.62%384.39%976.52%239.61%72.49%-
Selling, General & Admin
24.34M18.56M21M16.8M20.46M23.19M27.18M34.48M36.09M39.8M
SG&A % of Revenue
46.19%350.31%114.33%57.17%53.62%384.79%571.27%121.03%69.21%-
Research & Development
7.88M1.68M1.25M170K171K153K143K2.88M1.71M468K
R&D % of Revenue
14.95%31.74%6.82%0.58%0.45%2.54%3.01%10.09%3.28%-
Other Operating Expenses
1.11M4.34M-1.25M-170K-171K-177K19.14M30.9M0-2M
Operating Income
17.03M▲ 0%
-16.86M▼ 199.0%
-3.88M▲ 77.0%
12.42M▲ 419.6%
17.53M▲ 41.2%
-17.41M▼ 199.3%
-41.85M▼ 140.3%
-39.98M▲ 4.5%
11.38M▲ 128.5%
4.97M▲ 0%
Operating Margin %
32.32%-318.12%-21.15%42.25%45.94%-288.93%-879.53%-140.33%21.83%18.15%
Operating Income Growth %
127.67%-198.98%76.95%419.59%41.18%-199.34%-140.31%4.47%128.48%-
EBITDA
17.34M-16.83M-1.97M12.59M17.54M-17.14M-40.95M-39.76M14.36M8.29M
EBITDA Margin %
32.9%-317.55%-10.72%42.84%45.95%-284.39%-860.61%-139.57%27.53%30.26%
EBITDA Growth %
128.52%-197.07%88.29%738.98%39.31%-197.74%-138.9%2.9%136.11%123.51%
D&A (Non-Cash Add-back)
304K30K1.92M172K7K274K900K216K2.97M3.32M
EBIT
17.49M-12.56M-63K13.64M17.53M-17.12M-23.46M-5.64M11.38M38.53M
Net Interest Income
-1.24M-922K-1.92M-1.84M-461K694K-569K-13.84M-9.56M-12.44M
Interest Income
00000694K003.47M843K
Interest Expense
1.24M922K1.92M1.84M461K0569K13.84M13.03M13.28M
Other Income/Expense
-773K3.42M1.9M-619K-1.64M295K1.02M20.5M20.43M28.94M
Pretax Income
16.26M▲ 0%
-13.44M▼ 182.7%
-1.98M▲ 85.3%
11.8M▲ 695.2%
15.89M▲ 34.7%
-17.12M▼ 207.7%
-40.83M▼ 138.5%
-19.48M▲ 52.3%
31.82M▲ 263.3%
33.91M▲ 0%
Pretax Margin %
30.86%-253.65%-10.79%40.15%41.64%-284.04%-858.15%-68.38%61.01%123.72%
Income Tax
1.66M-98K0-1.5M91K-15K0-5.66M103K104K
Effective Tax Rate %
10.22%0.73%0%-12.72%0.57%0.09%0%29.05%0.32%0.31%
Net Income
14.6M▲ 0%
-13.34M▼ 191.4%
-1.98M▲ 85.1%
13.3M▲ 770.9%
15.8M▲ 18.8%
-17.1M▼ 208.3%
-40.83M▼ 138.7%
-13.82M▲ 66.2%
31.71M▲ 329.4%
33.81M▲ 0%
Net Margin %
27.7%-251.8%-10.79%45.25%41.4%-283.79%-858.15%-48.52%60.81%123.34%
Net Income Growth %
127.27%-191.42%85.15%770.94%18.8%-208.27%-138.72%66.15%329.45%1282.58%
Net Income (Continuing)
14.6M-13.34M-1.98M13.3M15.8M-17.1M-40.83M-13.82M31.71M33.81M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
0.73▲ 0%
-1.18▼ 261.6%
-0.88▲ 25.4%
0.78▲ 188.6%
0.65▼ 16.7%
-1.98▼ 404.6%
-4.04▼ 104.0%
-1.65▲ 59.2%
1.46▲ 188.5%
1.94▲ 0%
EPS Growth %
115.47%-261.64%25.42%188.64%-16.67%-404.62%-104.04%59.16%188.48%468.97%
EPS (Basic)
0.75-1.18-0.880.820.69-1.98-4.04-1.651.53-
Diluted Shares Outstanding
11.33M11.33M8.76M11.5M12.19M11.41M11.47M11.7M17.98M17.42M
Basic Shares Outstanding
11.33M11.33M8.76M10.67M11.29M11.41M11.47M11.7M17.98M11.89M
Dividend Payout Ratio
----------

XOMAP Balance Sheet

XOMA Corporation (XOMAP) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
44.2M47.63M59.97M88.06M96.97M61.25M169.31M125.6M117.26M118.75M
Cash & Short-Term Investments
43.47M45.78M56.69M84.22M94.1M58.16M153.45M105.18M82.91M94.96M
Cash Only
43.47M45.78M56.69M84.22M93.33M57.83M153.29M101.65M82.91M94.46M
Short-Term Investments
0000774K335K161K3.53M382K494K
Accounts Receivable
397K1.47M2.93M1.79M209K2.37M15.22M17.02M4.9M23.32M
Days Sales Outstanding
2.75101.1258.2822.222143.351.17K218.0134.27221.16
Inventory
0001.61M000000
Days Inventory Outstanding
---3.46K------
Other Current Assets
327K0002.05M725K160K1.33M29.45M473K
Total Non-Current Assets
740K16.16M35.75M37.22M69.59M79.13M64.99M95.67M155.44M153.11M
Property, Plant & Equipment
83K59K544K380K213K36K403K351K277K257K
Fixed Asset Turnover
634.82x89.81x33.77x77.33x179.15x167.42x11.81x81.16x188.26x95.84x
Goodwill
0000000000
Intangible Assets
0000015.15M025.91M44.76M43.86M
Long-Term Investments
0392K681K1.69M063.68M64.05M0106.38M314.11M
Other Non-Current Assets
657K15.71M34.53M35.15M69.38M63.94M533K69.41M4.03M3.88M
Total Assets
44.94M▲ 0%
63.78M▲ 41.9%
95.72M▲ 50.1%
125.28M▲ 30.9%
166.56M▲ 32.9%
140.38M▼ 15.7%
234.3M▲ 66.9%
221.28M▼ 5.6%
272.7M▲ 23.2%
271.86M▲ 0%
Asset Turnover
1.17x0.08x0.19x0.23x0.23x0.04x0.02x0.13x0.19x0.11x
Asset Growth %
56.69%41.95%50.07%30.88%32.95%-15.72%66.9%-5.56%23.24%60.7%
Total Current Liabilities
7.42M5.7M8.88M12.3M12.97M6.82M19.5M24.37M34.82M33.08M
Accounts Payable
1.68M1.24M614K456K1.07M524K653K1.05M2.21M3.53M
Days Payables Outstanding
77.82269.95178.86979.062.29K698.031.67K1.87K272.18561.28
Short-Term Debt
0789K5.18M8.09M005.54M11.39M14.99M16.41M
Deferred Revenue (Current)
1.41M1.29M1.89M1.45M1.64M1.9M2.11M1.36M1.27M4.02M
Other Current Liabilities
1.99M2.08M132K1.56M8.13M2.35M9.78M3M14.93M13.14M
Current Ratio
5.95x8.35x6.76x7.16x7.48x8.98x8.68x5.15x3.37x3.59x
Quick Ratio
5.95x8.35x6.76x7.03x7.48x8.98x8.68x5.15x3.37x3.59x
Cash Conversion Cycle
---2.5K------340.12
Total Non-Current Liabilities
31.73M39.3M42.86M26.56M11.72M9.55M126.08M114.98M133.92M125.89M
Long-Term Debt
14.57M21.69M27.09M12.76M00118.52M106.88M116.56M88.83M
Capital Lease Obligations
00408K229K34K0335K483K060.53M
Deferred Tax Liabilities
00000000103K255K
Other Non-Current Liabilities
32K590K43K50K0003.21M14.06M14.6M
Total Liabilities
39.15M45M51.74M38.86M24.69M16.37M145.58M139.36M168.74M158.96M
Total Debt
14.57M22.48M32.85M21.26M229K34K124.45M119.2M131.56M124.73M
Net Debt
-28.9M-23.3M-23.84M-62.96M-93.1M-57.79M-28.84M17.54M48.65M30.27M
Debt / Equity
2.52x1.20x0.75x0.25x0.00x0.00x1.40x1.46x1.27x1.10x
Debt / EBITDA
0.84x--1.69x0.01x---9.16x15.04x
Net Debt / EBITDA
-1.67x---5.00x-5.31x---3.39x3.65x
Interest Coverage
14.13x-13.62x-0.03x7.40x38.02x--41.24x-0.41x0.87x2.90x
Total Equity
5.79M▲ 0%
18.79M▲ 224.7%
43.99M▲ 134.2%
86.42M▲ 96.5%
141.88M▲ 64.2%
124.01M▼ 12.6%
88.72M▼ 28.5%
81.92M▼ 7.7%
103.96M▲ 26.9%
112.89M▲ 0%
Equity Growth %
112.26%224.66%134.17%96.47%64.16%-12.59%-28.46%-7.66%26.9%80.06%
Book Value per Share
0.511.665.027.5111.6410.877.737.005.786.48
Total Shareholders' Equity
5.79M18.79M43.99M86.42M141.88M124.01M88.72M81.92M103.96M112.89M
Common Stock
62K65K73K84K85K86K86K90K89K89K
Retained Earnings
-1.18B-1.19B-1.19B-1.18B-1.17B-1.18B-1.22B-1.24B-1.22B-1.22B
Treasury Stock
0000000000
Accumulated OCI
-41K00000073K53K119K
Minority Interest
0000000000

XOMAP Cash Flow Statement

XOMA Corporation (XOMAP) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
2.69M-12.64M-285K10.09M22.68M-12.88M-18.16M-13.75M2.87M6.63M
Operating CF Margin %
5.1%-238.61%-1.55%34.34%59.43%-213.69%-381.63%-48.26%5.51%-
Operating CF Growth %
107.97%-570.74%97.75%3641.05%124.71%-156.79%-40.99%24.29%120.88%316.27%
Net Income
14.6M-13.34M-1.98M13.3M15.8M-17.1M-40.83M-13.82M31.71M33.81M
Depreciation & Amortization
304K30K25K22K7K104K934K216K2.97M3.32M
Stock-Based Compensation
7.3M3.9M4.95M3.96M6.2M3.61M9.22M10.31M9.27M3.92M
Deferred Taxes
1.72M0-187K0000-5.66M103K153K
Other Non-Cash Items
-13.04M-251K1.01M-7.38M1.56M694K13.41M-2.01M-29.82M-20M
Working Capital Changes
-8.2M-2.98M-4.09M187K-886K-181K-898K-2.79M-11.37M-7.67M
Change in Receivables
169K-1.03M-1.56M1.14M1.58M208K-1M-835K-2.43M1.6M
Change in Inventory
001.56M0000000
Change in Payables
-6.55M-1.16M-242K-542K765K1.84M01.6M-10.6M-9.96M
Cash from Investing
1.61M-15.01M-19.3M-209K-26.5M-20.22M-711K-28.26M50.89M64.13M
Capital Expenditures
-8K-15.01M-19.3M-9K-26.5M-15.25M-17K-20K0-21.27M
CapEx % of Revenue
0.02%283.19%105.06%0.03%69.44%252.98%0.36%0.07%-77.61%
Acquisitions
1.61M000000-1.25M3.85M59.14M
Investments
----------
Other Investing
1.61M-15M0-200K0-4.97M-694K-23.75M47.13M19.27M
Cash from Financing
13.26M29.94M30.49M19.79M12.84M-4.45M120.59M-11.13M-26.46M-27.05M
Debt Issued (Net)
-16.43M7.49M8.55M-5.31M-4.25M0130M-6.9M-10.6M-11.92M
Equity Issued (Net)
30.18M22.33M22M24.6M40M0-148K-13K-7.33M-6.81M
Dividends Paid
0000-3.5M-5.47M-5.47M-5.47M-5.47M-5.53M
Share Repurchases
000000-148K-13K-16.04M-15.76M
Other Financing
-490K120K-54K506K-19.42M1.02M-3.79M1.26M-3.07M-2.79M
Net Change in Cash
17.73M▲ 0%
2.31M▼ 87.0%
10.91M▲ 372.4%
29.68M▲ 172.1%
9.01M▼ 69.6%
-37.55M▼ 516.6%
101.72M▲ 370.9%
-53.13M▼ 152.2%
27.29M▲ 151.4%
8.07M▲ 0%
Free Cash Flow
2.68M▲ 0%
-27.65M▼ 1132.5%
-19.59M▲ 29.2%
8.88M▲ 145.4%
-3.82M▼ 143.0%
-28.13M▼ 635.9%
-18.18M▲ 35.4%
-13.77M▲ 24.2%
2.87M▲ 120.9%
6.63M▲ 0%
FCF Margin %
5.08%-521.8%-106.61%30.23%-10.02%-466.67%-381.99%-48.33%5.51%24.2%
FCF Growth %
107.94%-1132.49%29.17%145.36%-143.03%-635.9%35.38%24.25%120.85%199.24%
FCF per Share
0.24-2.44-2.230.77-0.31-2.46-1.58-1.180.160.38
FCF Conversion (FCF/Net Income)
0.18x0.95x0.14x0.76x1.44x0.75x0.44x0.99x0.09x0.20x
Interest Paid
081K0692K311K009.98M00
Taxes Paid
01.64M00076K09.98M00

XOMAP Key Ratios

XOMA Corporation (XOMAP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
252.26%-108.61%-6.31%20.39%13.84%-12.87%-38.39%-16.2%34.12%32.41%
Return on Invested Capital (ROIC)
---37.28%42.71%36.4%-22.71%-49.78%-37.63%6.77%2.59%
Gross Margin
85.05%68.26%93.18%99.42%99.55%95.45%96.99%99.28%94.32%94.35%
Net Margin
27.7%-251.8%-10.79%45.25%41.4%-283.79%-858.15%-48.52%60.81%123.34%
Debt / Equity
2.52x1.20x0.75x0.25x0.00x0.00x1.40x1.46x1.27x1.10x
Interest Coverage
14.13x-13.62x-0.03x7.40x38.02x--41.24x-0.41x0.87x2.90x
FCF Conversion
0.18x0.95x0.14x0.76x1.44x0.75x0.44x0.99x0.09x0.20x
Revenue Growth
846.98%-89.94%246.67%59.96%29.86%-84.21%-21.06%498.72%83.06%-36.12%
Related:XOMAP Dividend History·XOMAP Revenue History·XOMAP Price History·XOMAP P/E History·XOMAP Financial Ratios·XOMAP Institutional Holders

XOMAP SEC Filings & Documents

XOMA Corporation (XOMAP) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 22, 2026·SEC

Material company update

May 18, 2026·SEC

Material company update

Apr 27, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 18, 2026·SEC

FY 2025

Mar 17, 2025·SEC

FY 2024

Mar 8, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 12, 2026·SEC

FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 13, 2025·SEC

XOMAP Frequently Asked Questions

XOMA Corporation (XOMAP) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

XOMA Corporation (XOMAP) reported $27.4M in revenue for fiscal year 2025. This represents a 661% increase from $3.6M in 1996.

XOMA Corporation (XOMAP) grew revenue by 83.1% over the past year. This is strong growth.

Yes, XOMA Corporation (XOMAP) is profitable, generating $33.8M in net income for fiscal year 2025 (60.8% net margin).

Dividend & Returns

Yes, XOMA Corporation (XOMAP) pays a dividend with a yield of 1.20%. This makes it attractive for income-focused investors.

XOMA Corporation (XOMAP) has a return on equity (ROE) of 34.1%. This is excellent, indicating efficient use of shareholder capital.

XOMA Corporation (XOMAP) generated $6.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in XOMAP back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →

How much would $100/month in XOMAP be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →